Harvard Biotechnology Club Awards NeuroHealing Pharmaceuticals First Prize in Business Plan Competition
Boston. In the 2004 biotechnology Business Plan Competition organized by the GSAS Harvard Biotechnology Club, NeuroHealing Pharmaceuticals Inc., a pharmaceutical company focused on the development of treatments for the neuro-rehabilitation market, was awarded first prize by the panel of judges comprised of members of leading venture capital firms.
At the awards ceremony hosted by Brown Rudnick Berlack Israels LLP, the judges described NeuroHealing's concept to be solid, novel and addressing an attractive, unserved market. Discussing the review of many outstanding companies, Patrick Loerch, the director of the competition, said
"NeuroHealing's excellent management team, experienced in the target market and development process, resulted in a clear winner this year." Judges included representatives from the following venture firms: BioVentures Investors, Boston Millennia Partners, CDP Capital, Flagship Ventures, MPM Capital, Oxford Bioscience Partners, Polaris Ventures and Versant Ventures.
"This award recognizes the founders, Daniel Katzman and Esteban Fridman's, innovative concept of the need for a drug therapy approach to the neuro- rehabilitation market, and the work of Elkan Gamzu, Chairman, Irit Aish and the entire team in establishing our clinical programs," said Neal Farber, CEO of NeuroHealing. "In addition, we thank the Harvard Biotechnology Club and the judges for this honor and exposure, as we progress in our fundraising efforts."
Other news from the department business & finance
